Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Persistency of response after long-term Xolair therapy in allergic asthma (XPORT)
2016-001001-16Phase 4
- Sponsor
- Roche
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in allergic asthma and asthma comparing Xolair continuation with Xolair discontinuation (placebo) (2 arms). Primary endpoint: Percentage of participants without protocol-defined severe exacerbation.
02
Drugs
omalizumab
03
Conditions
allergic asthmaasthma
Beyond the preview
Go deeper on 2016-001001-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001001-16.